3D NAMs and models in Translational Research
AGENDA OVERVIEW
Webinar Agenda – 50 minutes
Topic: Advancing Translational Research with advanced 3D Non Animal Models (NAMs)
0–20 mins | Expert Interview: Davide Danovi (TBC)
Davide Danovi, CSO, Migration Biotherapeutics, Visiting Senior Lecturer, King’s College London
A focused interview exploring the role of 3D NAMs in translational research, including disease relevance, phenotyping, and applications in drug discovery.
20–50 mins | Panel Discussion: Advancing Translational Research with 3D Non Animal Models(NAMs)
- Improving disease relevance with advanced 3D Non Animal Models (NAMs)
- Practical adoption of 3D models in drug discovery and cell therapy
- Bridging preclinical insights to clinical translation
Moderator: Davide Danovi, CSO, Migration Biotherapeutics, Senior Lecturer, King’s College London
Panellists:
- Peter Andersen, Chief Research & Development Officer, TreeFrog Therapeutics
- Timothy Lyden, Professor of Anatomy and Physiology , Director Tissue and Cellular Innovation Center, University of Wisconsin–River Falls
- Moin Saleem, Professor of Paediatric Renal Medicine; Founder and Chief Scientific Advisor, Purespring Therapeutics; University of Bristol and Bristol Royal Hospital for Children
Advancing CGT – Commercial & Regulatory Considerations
AGENDA OVERVIEW
Date Sept 14 , 2-2.50pm UK time
Advancing CGT – Commercial & Regulatory Considerations
Duration: 50 minutes
50 minutes mins | Panel Discussion: Advancing CGT – Commercial & Regulatory Considerations
- Balancing innovation, regulation and speed to market
- Building scalable manufacturing, quality and compliance strategies
- Commercialising advanced therapies in a challenging funding and access environment
Moderator: Konstantinos Gkatzis, Principal, UK & Europe, Epiceller
Panelists:
- Amir Hefni, CEO, Resolution Therapeutics
- Ruben Rizzi, Senior Vice President, Global Regulatory Affairs, BioNTech
- Christopher Middendorf, Senior Director, Technical, Pharma & Biotech GxP Compliance, Hogan Lovells
.jpg)
Biography:
Konstantinos is a biomedical scientist, venture capital fellow, bioethicist and founder of Epiceller, specializing in translational research, drug discovery, and healthcare investment. He has led multiple preclinical drug discovery programs and collaborates with global venture funds on biotech and digital health investments. He also serves as a scientific and ethic expert for non-profit organizations, supporting responsible and ethical innovation in medicine and emerging healthcare technologies.
